Karyopharm Therapeutics (KPTI) Reports In-Line Q3 EPS

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $0 , versus $30 thousand reported last year.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance
• Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance